Bernstein Reiterates Outperform Rating on Humana (HUM)

Bernstein SocGen Group analyst Lance Wilkes reiterated an Outperform rating and $313.00 price target on Humana (NYSE: HUM).

The analyst commented: "HUM reaffirms its 25 guide, a positive baby step for the industry toward recovery; We see the HUM reaffirmation as further support for an outlook of stable utilization in 2025. This is consistent with what we are observing from hospital reported results and insights from the payroll/capacity data which suggests modest deceleration in utilization. We note that HCA saw same store equiv admission of 2.8% in 1Q vs 5.2% prior year, even adjusting for leap year this is a deceleration consistent with their guidance. Overall, we see UNH’s recent announcements as the outlier, driven more by company specific issues, and we see the sector as beginning the recovery phase."

For an analyst ratings summary and ratings history on Humana click here. For more ratings news on Humana click here.

Shares of Humana closed at $231.39 yesterday.

You May Also Be Interested In

• First Advantage to join S&P SmallCap 600, replacing Kennedy-Wilson
• Adobe (ADBE) PT Lowered to $340 at JPMorgan
• Barclays Upgrades Avanza Bank Holding AB (AZA:SS) to Overweight